Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
AssigneeBiPar Sciences, Inc.
InventorsBarry M. Sherman, Charles Bradley, Valeria Ossovskaya
Life of this patent
Estimating the term…
Abstract
In one aspect, the present invention provides a method of treating breast cancer that is negative for at least one of ER, PR, or HER2, comprising administering to a subject at least one PARP inhibitor. In another aspect, the present invention provides a method of treating breast cancer comprising administering to a subject at least one PARP inhibitor in combination with at least one anti-tumor agent.
Claims121
A method of treating breast cancer that is negative for at least one of ER, PR, or HER2 in a patient, comprising administering to the patient at least one PARP inhibitor.
A method of treating breast cancer that is negative for at least one of ER, PR, or HER2 in a patient in need thereof, comprising:
- (a) obtaining a sample from the patient;
- (b) testing the sample to determine each of the following:
- (i) whether the cancer is ER-positive or ER negative;
- (ii) whether the cancer is PR-positive or PR negative;
- (iii) whether the cancer is HER2-positive or HER2 negative;
- (c) if the testing indicates that the cancer is negative for at least one of ER, PR, or HER2, treating the patient with at least one PARP inhibitor.
A method of treating breast cancer that is negative for at least one of ER, PR, or HER2 in a patient, comprising:
- (a) testing a sample from the patient for PARP expression;
- and
- (b) if the PARP expression exceeds a predetermined level, administering to the patient at least one PARP inhibitor.
A method of treating breast cancer in a patient, comprising administering to the patient at least one PARP inhibitor in combination with at least one anti-tumor agent.
A method of treating breast cancer in a patient in need thereof, comprising:
- (a) obtaining a sample from the patient;
- (b) testing the sample to determine each of the following:
- (i) whether the cancer is ER-positive or ER negative;
- (ii) whether the cancer is PR-positive or PR negative;
- (iii) whether the cancer is HER2-positive or HER2 negative;
- (c) if the testing indicates that the cancer is negative for at least one of ER, PR, or HER2, treating the patient with a combination of therapeutic agents, wherein the therapeutic agents include at least one PARP inhibitor and at least one anti-tumor agent.
A method of treating breast cancer in a patient, comprising:
- (a) testing a sample from the patient for PARP expression;
- and
- (b) if the PARP expression exceeds a predetermined level, administering to the patient at least one PARP inhibitor and at least one anti-tumor agent.
Dependencies are inferred from the claim text.